by Sermonix Pharmaceuticals | Apr 11, 2025 | News
COLUMBUS, Ohio, and SAN FRANCISCO, Nov. 02, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Quantum Leap Healthcare...
by Sermonix Pharmaceuticals | Mar 27, 2025 | News
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer COLUMBUS, Ohio and CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals, a privately held biopharmaceutical company...
by Sermonix Pharmaceuticals | Jan 29, 2025 | News
Lasofoxifene, but not fulvestrant, improved vaginal and vulvar symptoms in quality of life secondary endpoint analysis COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing...
by Sermonix Pharmaceuticals | Oct 21, 2024 | News
Sermonix will also present a poster on the results of its Phase 2 trial evaluating neoadjuvant lasofoxifene in molecularly selected HR+/HER2-, locally advanced breast cancer COLUMBUS, Ohio, Oct. 21, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a...
by Sermonix Pharmaceuticals | Aug 28, 2024 | News
COLUMBUS, Ohio and SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Quantum Leap Healthcare...
Recent Comments